Discovering New Anti-Infective Agents from Lysobacter
从溶杆菌中发现新的抗感染剂
基本信息
- 批准号:8875579
- 负责人:
- 金额:$ 21.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-15 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:Actinobacteria classAddressAgricultureAmidesAmino AcidsAnabolismAnti-Infective AgentsAntibioticsAntifungal AgentsAntifungal AntibioticsAttentionBacteriaBiochemicalBiocontrolsBiological FactorsChemical StructureChemicalsChemistryClinical ResearchCommunicable DiseasesComplexDaptomycinDevelopmentDisease OutbreaksDrug resistanceEmployee StrikesEngineeringEnzymesFamilyFatty AcidsGene ClusterGene ExpressionGenesGenomeGoalsGram-Positive BacteriaGrantHealthHumanHybridsInfectionLeadLifeLinkLogicLysobacterMembraneMolecularMorbidity - disease rateMulti-Drug ResistanceNatureOomycetesOrnithineOxidation-ReductionPeptidesPharmacologic SubstancePhaseProductionProductivityProteinsProteobacteriaReactionRegulationResearchResistanceResortSignal TransductionSoilSourceStreptomycesStructureSuperbugSystemTestingTimeVancomycinWaterbasedesigndihydromaltophilindrug developmentextracellularfungusgenome sequencinggliding bacteriahydroxy fatty acidmethicillin resistant Staphylococcus aureusmortalitynovelpathogenpeptide synthasepolyketide synthaseproduct developmentreceptorresearch studyscaffoldsmall molecule
项目摘要
DESCRIPTION (provided by applicant): Multi-drug resistance has become an increasingly important cause of mortality and morbidity in humans. It is a pressing and continual need to discover new anti-infective agents. Bioactive natural products are a major source of anti-infective drugs. Traditionally, soil bacteria, especially the Gram-positive Streptomyces, have been the primary source for bioactive natural products. However, many ubiquitous inhabitants of soil and water, such as the Gram-negative gliding bacteria Lysobacter, remain largely unexplored, even though they are prolific producers of natural products. This proposal describes a research plan to discover and evaluate new anti-infectives with novel structures and potent activities from the new sources. The focus is on deciphering their biosynthetic and regulatory mechanisms. Specifically, two groups of bioactive natural products, HSAF and WAP-8294A, will be investigated. HSAF (dihydromaltophilin) is a polycyclic tetramate macrolactam (PTM) and represents a novel type of antifungal compounds with new chemistry and new mode of action. To develop HSAF as a new type of antifungal antibiotics, it is important to understand the biosynthetic mechanism for the novel chemical structure. The HSAF biosynthetic gene cluster contains only a single-module polyketide synthase-nonribosomal peptide synthetase (PKS/NRPS), flanked by a cascade of six redox enzymes, although HSAF biosynthesis apparently requires two separate hexaketide chains that are linked together by one amino acid (ornithine) via two amide bonds. This system represents an unprecedented iterative PKS/NRPS hybrid. The goal here is to illustrate the reactions catalyzed by the "redox enzymes-modulated iterative PKS/NRPS", which lead to the distinct PTM structure. WAP-8294A are a complex of at least 20 cyclic lipodepsipeptides with a potent activity against Methicillin-Resistant Staphylococcus aureus (MRSA, ED5014 times more active than vancomycin, a "last resort" antibiotic). Due to a very low yield, only the major component of the complex, WAP-8294A2, is in clinical studies (by aRigen Pharmaceuticals). Although the compounds were first isolated nearly 15 years ago and one of them is in clinical studies, their biosynthetic genes were just identified in 2011. The goal here is to determine the molecular mechanisms for WAP biosynthesis and regulation, particularly the mechanism for fatty acid incorporation that leads to structural diversity. The understanding of the biosynthetic and regulatory mechanisms for HSAF and WAP-8294A is an essential step toward rational biosynthetic engineering, productivity improvement and structure-activity optimization of these two groups of very promising bioactive natural products. In addition, because Lysobacter are prolific natural product producers that have not been exploited, this research will open a new direction to discovering new anti-infective drugs.
描述(由申请人提供):多药耐药已成为人类死亡和发病的一个日益重要的原因。发现新的抗感染药物是一项迫切而持续的需要。生物活性天然产物是抗感染药物的主要来源。传统上,土壤细菌,特别是革兰氏阳性链霉菌,一直是生物活性天然产物的主要来源。然而,许多无处不在的土壤和水中的居民,如革兰氏阴性滑翔细菌溶菌,尽管它们是天然产物的多产生产者,但它们在很大程度上仍未被探索。本提案描述了从新来源发现和评估具有新结构和有效活性的新抗感染药物的研究计划。重点是破译它们的生物合成和调节机制。具体而言,将研究两组生物活性天然产物HSAF和WAP-8294A。HSAF (dihydromaltophilin)是一种多环四聚乳酸大内酰胺(PTM),是一类具有新化学性质和新作用方式的新型抗真菌化合物。为了使HSAF成为一种新型的抗真菌药物,了解其化学结构的生物合成机制是十分重要的。HSAF生物合成基因簇仅包含一个单模块聚酮合成酶-非核糖体肽合成酶(PKS/NRPS),其两侧有六个氧化还原酶级联,尽管HSAF生物合成显然需要两个独立的六肽链,它们通过两个酰胺键由一个氨基酸(鸟氨酸)连接在一起。该系统代表了前所未有的迭代PKS/NRPS混合系统。本文的目的是阐明由“氧化还原酶调控的迭代PKS/NRPS”催化的反应,从而导致独特的PTM结构。WAP-8294A是至少20个环状脂沉肽的复合物,对耐甲氧西林金黄色葡萄球菌(MRSA, ED5014比万古霉素(一种“最后手段”抗生素)活性高)具有有效活性。由于产率非常低,只有该复合物的主要成分WAP-8294A2(由aRigen制药公司)处于临床研究中。尽管这些化合物在近15年前首次被分离出来,其中一种化合物正在临床研究中,但它们的生物合成基因直到2011年才被发现。目的是确定WAP生物合成和调控的分子机制,特别是脂肪酸掺入导致结构多样性的机制。了解HSAF和WAP-8294A的生物合成及其调控机制,是对这两类极具生物活性的天然产物进行合理的生物合成工程、提高生产效率和优化结构活性的重要一步。此外,由于溶杆菌是尚未开发的多产的天然产物生产者,本研究将为发现新的抗感染药物开辟新的方向。
项目成果
期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transcriptomic analysis reveals new regulatory roles of Clp signaling in secondary metabolite biosynthesis and surface motility in Lysobacter enzymogenes OH11.
转录组分析揭示了 Clp 信号在溶杆菌 OH11 次生代谢物生物合成和表面运动中的新调节作用
- DOI:10.1007/s00253-014-6072-1
- 发表时间:2014-11
- 期刊:
- 影响因子:5
- 作者:Wang, Yansheng;Zhao, Yuxin;Zhang, Juan;Zhao, Yangyang;Shen, Yan;Su, Zhenhe;Xu, Gaoge;Du, Liangcheng;Huffman, Justin M.;Venturi, Vittorio;Qian, Guoliang;Liu, Fengquan
- 通讯作者:Liu, Fengquan
HSAF-induced antifungal effects in Candida albicans through ROS-mediated apoptosis.
HSAF 通过 ROS 介导的细胞凋亡在白色念珠菌中诱导抗真菌作用。
- DOI:10.1039/c5ra26092b
- 发表时间:2016
- 期刊:
- 影响因子:3.9
- 作者:Ding Y;Li Z;Li Y;Lu C;Wang H;Shen Y;Du L
- 通讯作者:Du L
Yield Improvement of the Anti-MRSA Antibiotics WAP-8294A by CRISPR/dCas9 Combined with Refactoring Self-Protection Genes in Lysobacter enzymogenes OH11.
CRISPR/DCAS9的抗MRSA抗生素WAP-8294A的产生改善,并在溶血杆菌酶OH11中结合了重构自我保护基因。
- DOI:10.1021/acssynbio.7b00293
- 发表时间:2018-01-19
- 期刊:
- 影响因子:4.7
- 作者:Yu L;Su W;Fey PD;Liu F;Du L
- 通讯作者:Du L
Bioactive natural products from Lysobacter.
- DOI:10.1039/c2np20064c
- 发表时间:2012-11
- 期刊:
- 影响因子:11.9
- 作者:Xie Y;Wright S;Shen Y;Du L
- 通讯作者:Du L
Activation of a Cryptic Gene Cluster in Lysobacter enzymogenes Reveals a Module/Domain Portable Mechanism of Nonribosomal Peptide Synthetases in the Biosynthesis of Pyrrolopyrazines.
- DOI:10.1021/acs.orglett.7b01611
- 发表时间:2017-10-06
- 期刊:
- 影响因子:5.2
- 作者:Li S;Wu X;Zhang L;Shen Y;Du L
- 通讯作者:Du L
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LIANGCHENG DU其他文献
LIANGCHENG DU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LIANGCHENG DU', 18)}}的其他基金
Discovering New Anti-Infective Agents from Lysobacter
从溶杆菌中发现新的抗感染剂
- 批准号:
8485539 - 财政年份:2012
- 资助金额:
$ 21.44万 - 项目类别:
Discovering New Anti-Infective Agents from Lysobacter
从溶杆菌中发现新的抗感染剂
- 批准号:
8662183 - 财政年份:2012
- 资助金额:
$ 21.44万 - 项目类别:
Discovering New Anti-Infective Agents from Lysobacter
从溶杆菌中发现新的抗感染剂
- 批准号:
8373166 - 财政年份:2012
- 资助金额:
$ 21.44万 - 项目类别:
Biosynthesis of HSAF, an antifungal natural product with a novel mode of action
具有新颖作用方式的抗真菌天然产物 HSAF 的生物合成
- 批准号:
7875523 - 财政年份:2009
- 资助金额:
$ 21.44万 - 项目类别:
Biosynthesis of HSAF, an antifungal natural product with a novel mode of action
具有新颖作用方式的抗真菌天然产物 HSAF 的生物合成
- 批准号:
7471681 - 财政年份:2008
- 资助金额:
$ 21.44万 - 项目类别:
Biosynthesis of HSAF, an antifungal natural product with a novel mode of action
具有新颖作用方式的抗真菌天然产物 HSAF 的生物合成
- 批准号:
7638002 - 财政年份:2008
- 资助金额:
$ 21.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Research Grant